miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2

MINGFEI LI1*, YUAN YANG2*, YU KUANG2, XIANFENG GAN1, WEI ZENG2, YUPING LIU3 and HUA GUAN3

1Department of Hepatobiliary Surgery, Sichuan Provincial People's Hospital; 2Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University; 3Health Management Center, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China

Received November 18, 2015; Accepted November 25, 2016

DOI: 10.3892/etm.2017.4244

Abstract. Hepatocellular carcinoma (HCC) is currently ranked as the third leading cause of cancer-related mortality worldwide. microRNAs (miRs) serve important roles in the development and progression of HCC. miR-365 has been demonstrated to function as a tumor suppressor in several types of cancer, including HCC; however, the mechanisms by which miR-365 regulates HCC apoptosis remains to be elucidated. In the present study, reverse transcription-quantitative polymerase chain reaction was performed to determine miR-365 expression levels in HCC and normal liver (LO2) cells. miR-365 overexpression was induced in SMC7721 cells using a plasmid-based system, and Cell Counting Kit-8 and TUNEL assays were performed to detect cell activity and apoptosis following miR-365 transfection. A luciferase assay was performed to determine the direct target of miR-365 in apoptosis regulation. Furthermore, a subcutaneously transplanted tumor model was established to evaluate the effects of miR-365 on tumor growth in vivo. The tumor tissue was used for further proliferation and apoptosis detection. The results of the present study indicated that miR-365 expression was significantly lower in HCC cells compared with LO2 cells (P<0.01). Transfection of SMC7721 cells with miR-365 plasmid significantly inhibited cell activity by inducing apoptosis (P<0.01). Luciferase assay indicated that miR-365 targets B-cell lymphoma 2 (Bcl-2) directly and therefore induces the downstream expression of pro-apoptotic proteins. The SMC7721 primary tumor growth was significantly reduced by miR-365 transfection (P<0.01). Further investigation demonstrated that the miR-365 group contained significantly fewer cells that were positive for proliferating cell nuclear antigen (P<0.01) and significantly more apoptotic cells (P<0.01). In conclusion, the results of the present study demonstrated that miR-365 may serve a role in inducing HCC apoptosis via directly targeting Bcl-2. This may provide a novel diagnosis and therapy target for the treatment of patients with HCC.

Introduction

Human hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer, ranking as the fifth most prevalent cancer and the third leading cause of cancer mortality worldwide (1). In 2012, 782,000 new cases and 746,000 incidences of mortality due to HCC were reported (1). Imaging techniques, including contrast-enhanced ultrasonography, multidetector computer tomography and diffusion weighted magnetic resonance imaging, have markedly improved the detection of HCC, with limitations of <2 cm in diameter in the case of liver tumors (2). Meanwhile, several serum biomarkers, such as α-fetoprotein and des-γ-carboxy-prothrombin, have been established to outline a set of guidelines for an early liver cancer diagnosis and long-term prognosis (3). However, the majority of patients are diagnosed in the later stages of HCC, therefore, few are eligible for curative treatments (4). Local ablative therapies, including radiofrequency ablation and transarterial chemoembolization, are used when tumors are localized within the liver, whereas sorafenib, a multikinase-inhibitor, is the only approved systemic therapy for the treatment of patients with advanced HCC (5,6). Thus, increased understanding of the molecular mechanisms responsible may be useful to clarify the role of new targets for the treatment and prognosis of HCC.

microRNAs (miRNAs or miRs) are highly conserved, short, single-stranded RNA molecules (20-22 nucleotides) which negatively modulate gene transcription via binding to mRNA targets. Previous studies have demonstrated that miRNAs serve crucial roles in the mechanisms underlying tumor development, progression, and resistance to anti-tumor agents (4,7-9). Dysregulation of miRNA expression has been documented in patients with HCC and unique patterns of
miRNA expression have been established as potential markers for the prognosis, diagnosis, sub-classification and therapeutic targets of HCC (4,10,11).

miR-365 has previously been demonstrated to function as a tumor suppressor in several types of cancer, including HCC (12,13). miR-365 has been found to be highly expressed in invasive ductal adenocarcinoma, and to induce ganciclovir resistance in pancreatic cancer cells through directly targeting adaptor protein Src homology 2 domain containing 1 and apoptosis-promoting protein BAX (12). In addition, miR-365 levels were found to be decreased in colon cancer, and restoration of miR-365 expression inhibited cell cycle progression, promoted 5-fluorouracil-induced apoptosis and repressed tumorigenicity in colon cancer cell lines (13). A recent study suggested that miR-365 expression is inversely correlated with poor prognosis and survival rates of patients with HCC via inhibiting cell proliferation (14). However, the role of miR-365 in regulating apoptosis of HCC cells remains unclear.

In the present study, the expression of miR-365 in HCC cell lines was investigated and it was determined that miR-365 expression is decreased in HCC cells. Overexpression of miR-365 in HCC cells inhibited tumor growth in vitro and in vivo through directly targeting Bcl-2 and inducing apoptosis. Thus, the present study demonstrated that miR-365 is a novel diagnosis and therapy target for the treatment of patients with HCC.

Materials and methods

Vector construction. miR-365 expression plasmids and negative control (miR-NC) plasmids were obtained from Guangzhou Fulengen Co., Ltd. (Guangzhou, China). Plasmids were extracted from DH5α E. coli transformants using EndoFree Plasmid Giga kits (Qiagen GmbH, Hilden, Germany) and stored at -20°C prior to use. The concentration was determined by measuring the A260/A280 ratio using UV spectrophotometry.

Cell line and transfection conditions. The HCC cell lines used were SMMC7221, HepG2, Bel-7404 and Bel-7402, and the normal hepatocellular cell line was LO2 (all ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and maintained in a humidified atmosphere containing 5% CO2 at 37°C. Cell transfection was carried out using FuGENE HD Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's protocol. Cells were harvested 48 h post-transfection for reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting and TUNEL assay analysis. After transfection for 48 h, puromycin (2 µg/ml; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) was added into the medium to ensure the stable expression cells. All transfections were performed in triplicate.

Target prediction. The miRWalk database (http://www. obrc/index.php?page=URL1154033362) and Targetscan (targetscan. org/vert_71/) were used for target prediction.

RNA extraction and RT-qPCR. Total RNA was extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA concentration was assessed spectrophotometrically at 260 nm (ND 2000; Thermo Fisher Scientific, Inc.). RT was performed on the isolated total RNA using an RT kit (cat. no. RR047A; Takara Bio, Inc., Otsu, Japan) and qPCR was performed using a qPCR kit (cat. no. RR820A; Takara Bio, Inc.). gDNA eraser (1 µl, supplied in the aforementioned kit), 5X gDNA eraser buffer (2 µl) and mRNA template (2 µg) were added into one well. Then RNAase-free H2O was added to the final volume (10 µl), followed by incubation at room temperature for 5 min. RT was performed at 65°C for 5 min, 30°C for 10 min, 42°C for 10-30 min and 2°C for 3 min. PCR reaction contained SYBR Premix Ex Taq II buffer (10 µl), forward primer, reverse primer, DNA template and ddH2O. The final volume was 20 µl. qPCR conditions were as follows: Denaturation at 94°C for 2 min; amplification for 30 cycles at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 1 min. This was followed by a terminal elongation step at 72°C for 10 min, and performed using a Bio-Rad CFX96 thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA). U6 was used as an internal control, the Cq value of each qPCR product was calculated and the fold change was analyzed (15). The miR-365 and U6 primers were supplied by Guangzhou Ribobio Co., Ltd. (Guangzhou, China); primer sequences (cat. no. 10211; Bulge-Loop™ miRNA qRT-PCR Primer Set) are not supplied due to the company rules. All experiments were performed in triplicate.

Cell viability detection assay. The Cell Counting Kit-8 (CCK-8) assay (Beyotime Institute of Biotechnology, Haimen, China) was performed to detect cell viability. Absorbance was measured at 450 nm and each experiment was performed three times.

TUNEL assay. A TUNEL assay was performed to detect apoptotic cells in SMMC7221 cells and tumor tissues using a DeadEnd Fluorometric TUNEL system (Promega Corp., Madison, WI, USA) according to the manufacturer's protocol. A total of 1x10⁶ cells were seeded in a 6-well plate and cultured with DMEM supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.). A total of 24 h after cells were seeded, miR-NC or miR-365 were used to transfect the cells; 48 h post-transfection, the cells were washed with PBS (Zsio, Beijing, China) and fixed with the buffer supplied in the kit (Promega Corp.). Cell nuclei were stained with DAPI (Beyotime Institute of Biotechnology) at 25°C for 10 min. Glycerinum (Beyotime Institute of Biotechnology) at 25°C for 10 min. Glycerinum (Beyotime Institute of Biotechnology) at 25°C for 10 min. Glycerinum (Beyotime Institute of Biotechnology) was used to mount the slides. TUNEL-positive nuclei were defined as those with dark green fluorescent staining and these were identified via fluorescence microscopy. To quantify TUNEL-positive cells, the number of green fluorescence-positive cells was counted in 4-6 random fields at x200 magnification. Cell nuclei were counterstained with 4,6-diamidino-2-phenylindole (Beyotime Institute of Biotechnology).

 Luciferase assays. The miR-365 binding site was synthesized and cloned into an Ambion pMIR-REPORT vector.
Western blotting. Cells were lysed on ice (4°C) for 30 min with radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology) (containing 50 mM Tris-HCl, pH 7.4, 1% NP-40; 0.25% Na-deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM phenylmethane sulfonl fluoride; 1 µg/ml aprotinin; 1 µg/ml leupeptin; 1 µg/ml pepstatin; 1 mM Na3VO4; and 1 mM NaF). Centrifugation was performed at 4°C (12,000 x g) for 15 min. Protein concentration was determined by a BCA kit (Beyotime Institute of Biotechnology). A total of 20 µg protein was separated by 10% SDS-PAGE and electronically transferred onto a polyvinylidene difluoride membrane (EMD Millipore, Billerica MA, USA). Membranes were blocked with TBS/T buffer containing 5% non-fat milk at 25°C for 1 h and subsequently incubated at 25°C for 1 h with recommended dilution primary antibodies against Bcl-2 (cat. no. 15071; 1:1,000), Bcl-2-like protein 4 (Bax) (cat. no. 2772; 1:800), cytochrome (cyto) C (cat. no. 11940; 1:800), cleaved caspase 3 (cat no. 9661; 1:600) (all Cell Signaling Technology, Inc., Danvers, MA, USA); and GAPDH (cat. no. sc-25778; 1:10,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), at 37°C for 1 h followed by incubation with peroxidase-conjugated secondary antibodies (cat. no. TA100015; 1:10,000; OriGene Technologies, Inc., Beijing, China) at 37°C for 1 h. Peroxidase-labeled bands were visualized using an enhanced chemiluminescence kit (cat. no. WBKL S0050, EMD Millipore). Experiments were performed in triplicate. The bands were analyzed using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA).

Animal study. All animal research was approved by the Sichuan Provincial People’s Hospital Committee on Animal Research. The mice (8 mice and 4 mice in each group) were housed at 26°C under a 12-h light/dark cycle with ad libitum access to food and water. To establish the SMC7721 subcutaneous cancer model, 6x10³ SMC7721 cells transfected with miR-365 or miR-NC were injected subcutaneously into the right flank of six-week-old female BALB/c nude mice (4 mice per group). Tumor diameters were measured once per week. Tumor volume was estimated using the formula: Tumor volume (mm³) = length (mm) x [width (mm)]² x 1/2 as indicated in a (16). The weight, appetite, and behavior of the mice were observed. At 35 days after tumor cell injection, the mice were anesthetized using diethyl ether (100 mg/kg; Sigma-Aldrich) and sacrificed and tumors were dissected and weighed. Animal studies were performed in accordance the guidelines set out by the Academic Medical Center of Sichuan province hospital (Chengdu, China).

miR-365 induces HCC cell apoptosis in vitro. In the present study, RT-qPCR was used to determine levels of miR-365 expression in HCC cells, including SMC7721, HepG2, Bel7404 and Bel7402, and the normal hepatocellular cell line LO2. The results demonstrated that miR-365 expression was significantly lower in HCC cells compared with LO2 cells (P<0.01; Fig. 1A). Transfection of the miR-365 expression plasmid into SMC7721 cells induced a significant upregulation in mature miR-365 of ~16-fold compared with the miR-NC transfected group (P<0.01; Fig. 1B). Following transfection, cells underwent CCK-8 and TUNEL assays. The results indicated that miR-365 markedly inhibited SMC7721 activity at 24 and 48 h post-transfection, and induced a significant decrease in activity at 72 h post-transfection compared with the NC group (P<0.01; Fig. 1C). Furthermore, TUNEL assay results indicated that significantly more apoptotic cells were present in the miR-365-transfected group compared with the miR-NC group (P<0.01; Fig. 1D). These results indicate that miR-365 may be a tumor suppressor in HCC cell in vitro.

Bcl-2 is a direct target of miR-365. To determine the targets of miR-365, a large number of potential target proteins in a database library were screened to identify potential putative mRNA binding sequences within the 3'-UTR. Using bioinformatics analysis (Targetscan micro, RNA.org and microRNASeq), it was demonstrated that Bcl-2 may be the direct target of miR-365 (Fig. 2A). To verify this, the
Bcl-2-3’UTR containing miR-365 binding site was cloned downstream of the luciferase open reading frame and the Bcl-2-3’UTR mutant, which also contained the mutated miR-365 binding site, was also introduced into the luciferase construct. The plasmid expressing miR-365 was transfected into 293T cells, and puromycin was used to select stable expression cells. The RT-qPCR results confirmed that miR-365 was significantly upregulated in the miR-365 cells compared with
the NC group (P<0.01; Fig. 2B). Luciferase-Bcl-2-3'UTR and luciferase-Bcl-2-3'UTR mutant constructs were subsequently transfected into 293T cells with stable miR-365 expression. At 4-6 h post-transfection, it was demonstrated that luciferase expression in Bcl‑2‑3'UTR constructs was significantly lower in the miR‑365 group compared with the NC group (P<0.01; Fig. 2C). By contrast, a consistent reduction in luciferase expression was not observed in cells transfected with the miRNA binding site mutant plasmids (Fig. 2C). Furthermore, western blotting results indicated that Bcl-2 expression was markedly inhibited by miR-365 in SMC7721 cells (Fig. 2D). The expression of pro-apoptotic proteins including Bax, cyt C and cleaved caspase 3, which are the downstream targets of Bcl-2, were markedly upregulated by miR-365. These results indicate that miR-365 may directly target Bcl-2 and therefore regulate the expression of downstream targets.

Overexpression of miR-365 inhibits HCC primary tumor growth in vivo. To determine the effect of miR-365 on tumor growth in vivo, SMC7721 cells that stably expressed miR-365 and miR-NC were used to establish the subcutaneous transplanted tumor model (Fig. 3A). As illustrated in Fig. 3B and C, miR-365 significantly inhibited SMC7721 tumor growth compared with the miR-NC group (P<0.01). At the end of the experiment, the volume of miR-365 group tumors were 37.4% of those in the miR-NC group. Furthermore, tumor weight was measured at the termination of the animal experiment, and mean tumor weight was found to be 0.43±0.13 and 1.13±0.18 g in the miR-365 and miR-NC groups, respectively, indicating that miR-365 significantly inhibited SMC7721 primary tumor growth in vivo compared with the miR-NC group (P<0.01; Fig. 3D).

miR-365 induces apoptosis and inhibits proliferation of HCC cells in vivo. PCNA staining and TUNEL assay were used to evaluate cell proliferation and apoptosis in SMC7721 primary tumors. As illustrated in Fig. 4A, significantly fewer PCNA positive cells were observed in the miR-365 group compared with the miR-NC group (P<0.01); however, more apoptotic
cells were present in the miR-365 group compared with the miR-NC group (P<0.01; Fig. 4B).

Discussion

miRNA is widely researched as an effective diagnosis biomarker and therapy target for several diseases, particularly cancer (17). Developing novel miRNA targets for cancer diagnosis and therapy is therefore of great scientific and economic significance. In the present study, it was demonstrated that miR-365 is downregulated in most HCC cancer cells compared with normal liver LO2 cells. Overexpression of miR-365 in SMC7721 cells was demonstrated to significantly inhibit cell growth in vitro and primary tumor growth in vivo by inducing apoptosis. Further investigation into the underlying mechanisms for this indicated that Bcl-2 is a direct target of miR-365.

Unique patterns of miRNA expression are valuable as potential markers for the diagnosis, prognosis, staging, and prediction of therapeutic responses in patients with HCC (8,18). A number of previous studies have revealed the presence of extensive and frequent miRNA dysregulation in cirrhosis, liver adenoma, and different stages of liver cancer (4,10,11,19,20). The miR-17-92 cluster, miR-21, miR-221, miR-222 and miR-224 have consistently been demonstrated to be upregulated in primary HCC samples (4,21); however, members of the lethal-7 and miR-200 families, as well as miR-29, miR-122, miR-124, and miR-199a/b, are typically downregulated in HCC cells (4,22), and miR-24 and miR-27a are typically downregulated in HCCs that exhibit with cirrhotic liver tissues (23). The downregulation of miR-24 in cirrhotic viral-associated HCC primary tissues is associated with a worse prognosis (24,25). miR-365 expression has been demonstrated to inversely correlate with poor prognosis and survival of patients with HCC via inhibiting cell proliferation (14). In the present study, it was demonstrated that miR-365 was able to significantly induce SMC7721 cell apoptosis in vitro and SMC7721 primary tumor tissue apoptosis in vivo. These results suggest that miR-365 has an antitumor role in HCC progression, which is consistent with a recent report (14).

Apoptosis is highly programmed cell death with distinct biochemical and genetic pathways that serves a critical role in development and homeostasis of normal tissues (26). It is well known that Bcl-2 functions as an anti-apoptotic protein in the progression of several diseases (27) and it has previously been demonstrated that Bcl-2 is an effective target for cancer therapy in several types of cancer (27,28). In the present study a luciferase assay was performed, which indicated that Bcl-2 may be a direct target of miR-365. Further investigation indicated that miR-365 overexpression in SMC7721 cells was able to inhibit Bcl-2 expression, whereas the expression of Bcl-2 downstream pro-apoptotic protein targets was markedly increased by miR-365. Nie et al (13) previously demonstrated that miR-365 expression was downregulated in colon cancer and that overexpression of miR-365 in colon cancer was able to significantly inhibit cell cycle progression and promote apoptosis of colon cancer cells, possibly by targeting cyclin D1 and Bcl-2. Furthermore, it has been demonstrated that miR-365 is able to modulate apoptosis and Bcl-2 expression in human umbilical vein endothelial cells treated with oxidized low-density lipoproteins (29). The results of the present study demonstrated that miR-365 may inhibit Bcl-2 expression in HCC, and suggested that the regulatory function of miR-365 in cancer is achieved by influencing Bcl-2 expression. Notably, the results of the present study may lead to a better understanding of the biological function of miR-365 in HCC development.

Acknowledgements

The present study was supported by the Youth Science Fund of the Sichuan Provincial People’s Hospital (grant no. 3030503061).

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Ariff B, Lloyd CR, Khan S, Shariff M, Thillainayagam AV, Banski DS, Khan SA, Taylor-Robinson SD and Lim AK: Imaging of liver cancer. World J Gastroenterol 15: 1289-1300, 2009.
3. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, et al: Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110-118, 2009.
4. Borel F, Konstantinova P and Jansen PL: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56: 1371-1383, 2012.
5. Brux J, Llovet JM, Castells A, Montañá X, Brit C, Ayuso MC, Vilana R and Rodés J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 27: 1578-1583, 1998.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
7. Ambros V: microRNAs: Tiny regulators with great potential. Cell 107: 823-826, 2002.
8. Anwar SL and Lehmann U: MicroRNAs: Emerging novel clinical biomarkers for hepatocellular carcinomas. J Clin Med 4: 1631-1650, 2015.
9. He J, Zhao K, Zheng L, Xu Z, Gong W, Chen S, Shen X, Huang G, Gao M, Zeng Y, et al: Upregulation of microRNA-122b by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol Cancer 14: 163, 2015.
10. Giordano S and Colombano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Exp Biol Med 327: 10513-10518, 2012.
11. Wang XW, Heegaard NH and Orum H: MicroRNAs in liver disease. Gastroenterology 142: 1431-1443, 2012.
12. Hamada S, Masumune A, Miura S, Satoh K and Shimosegawa T: MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell Signal 26: 179-185, 2014.
13. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X and Han W: microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 33: 220-225, 2012.
14. Chen Z, Huang Z, Ye Q, Ming Y, Zhang S, Zhao Y, Liu L, Wang Q and Cheng K: Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma. Int J Clin Exp Pathol 8: 1705-1711, 2015.
15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) Method. Methods 25: 402-408, 2001.
16. Dai L, Cui X, Zhang X, Cheng L, Liu Y, Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin. Nat Commun 7: 11996, 2016.
17. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
18. Ghidini M and Braconi C: Non-Coding RNAs in primary liver cancer. Front Med (Lausanne) 2: 36, 2015.
19. Wei R, Huang GL, Zhang MY, Li BK, Zhang HZ, Shi M, Chen XQ, Huang L, Zhou QM, Jia WH, et al: Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma. Clin Cancer Res 19: 4780-4791, 2013.
20. Wong CM, Wong CC, Lee JM, Fan DN, Au SL and Ng IO: Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 55: 1453-1461, 2012.
21. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S and Zucman-Rossi J: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963, 2008.
22. Huang S and He X: The role of microRNAs in liver cancer progression. Br J Cancer 104: 235-240, 2011.
23. Salvi A, Abeni E, Portolani N, Barlati S and De Petro G: Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol 42: 391-402, 2013.
24. Meng FL, Wang W and Jia WD: Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma. Med Oncol 31: 177, 2014.
25. Ma Y, She XG, Ming YZ and Wan QQ: miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour Biol 35: 10731-10736, 2014.
26. Lockshin RA and Williams CM: Programmed cell death-i. Cytology of degeneration in the intersegmental muscles of the perny silkmoth. J Insect Physiol 11: 123-133, 1965.
27. Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014: 150845, 2014.
28. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, Wang XY, Dent P, Reed JC, Pellecchia M, et al: Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17: 61-75, 2013.
29. Qin B, Xiao B, Liang D, Xia J, Li Y and Yang H: MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expression. Biochem Biophys Res Commun 410: 127-133, 2011.